Chief Technology Officer · AbCellera Biologics Inc. (ABCL)

Véronique Lecault

A named executive officer of AbCellera Biologics in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,315,758

FY2024: $3,424,564

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Véronique Lecault compensation by year

AbCellera Biologics Summary Compensation Table · all 4 fiscal years held
In US dollars, as AbCellera Biologics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$450,000$460,000$460,000$454,000
Bonus$172,627$167,779$184,666$204,402
Stock awards$0—$0$0
Option awards$4,043,114—$2,756,858$1,634,113
Non-equity incentive——$0$0
Pension and deferred compensation$0—$0$0
All other$22,447$22,808$23,040$23,244
Total$4,688,188$650,587$3,424,564$2,315,758

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AbCellera Biologics Inc. DEF 14A filed April 29, 2026, accession 0001703057-26-000020, and prior-year filings. Open the filing on EDGAR.

$4.7M
$651K
$3.4M
$2.3M
FY22
FY23
FY24
FY25
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option401,259—$5.39
Option832,033—$2.93
Option115,634—$13.18

Per the Outstanding Equity Awards at Fiscal Year-End table in AbCellera Biologics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments AbCellera Biologics discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$450,000$0$1,604$451,604
Change in control and involuntary termination$630,000$7,825,707$1,604$8,457,311

Per the Potential Payments Upon Termination or Change in Control table in AbCellera Biologics Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

AbCellera Biologics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Carl HansenChief Executive Officer$6,293,085
Andrew BoothChief Financial Officer$3,382,244
Tryn StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer$2,343,388
Véronique Lecault · this pageChief Technology Officer$2,315,758

The full AbCellera Biologics compensation record

free company brief

This page is one person within AbCellera Biologics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order AbCellera Biologics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AbCellera Biologics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy